bioRxiv · 10.64898/2026.11.12.760042
De novo design of antiviral monobody binders
Abstract
Monobodies (Mobs) are a class of immunoglobulin (Ig)-like proteins that have emerged as promising therapeutic scaffolds for applications ranging from antiviral therapy to cancer treatment. Unlike conventional monoclonal antibodies (mAbs), Mobs can be readily expressed in Escherichia coli at high yields, offering important advantages in overall developability. However, discovering antigen-specific Mobs with high binding affinity traditionally requires screening large, randomized in vitro libraries. To optimize Mob discovery, we developed MobGen, a computational pipeline for de novo design of Mob binders against viral antigens. As a proof of concept, we generated Mobs that bind the SARS-CoV-2 Spike glycoprotein Receptor Binding Domain (RBD). Subsequent in silico optimization improved production yield, thermal and conformational stability, binding affinity, and antiviral activity, demonstrating a promising approach for rapidly developing antibody-like molecules that target viral entry. These findings highlight MobGen's potential for de novo design of Mobs against emerging viruses with pandemic potential.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Moreira, P., Xiao, S., Conceicao, C. J. F., Alenquer, M., Silva, D. H., Parada, M., Marques, M. C., Schimdt, J., Buga, C. C., Cruz-Oliveira, C., Rodrigues, J., Miranda, M. P. d., Vieira-da-Silva, B., Wei, Y., Collado, J., Rodriguez-Espinosa, M. J., Arranz, R., Georgeon, S., Santiago, C., Valpuesta, J. M., Veiga, A. S., Castanho, M. A. R. B., Abreu, I. A., Amorim, M. J., Vicente, J. B., Correia, B. E., Soares, C. M., Lousa, D.. 2026-11-16. De novo design of antiviral monobody binders. https://doi.org/10.64898/2026.11.12.760042
Cite the original work for its findings. Save a collection to share your selection of sources.